Zucara Therapeutics
Zucara Therapeutics is developing ZT-01, a first-in-class, once-daily therapeutic to prevent hypoglycemia in people with Type 1 diabetes and insulin-dependent Type 2 diabetes. ZT-01 is designed to inhibit somatostatin, a pancreatic hormone that impairs the glucagon response to hypoglycemia. The goal is to restore glucagon secretion and prevent hypoglycemia.
Funding Round: Series B
Funding Amount: $25M
Date: 01-May-2025
Investors: The T1D Fund, Sanofi, The Perceptive Xontogeny Venture Fund (PXV Fund I)
Markets: Healthtech, Biotech, Diabetes, Pharmaceutical
HQ: Toronto, Ontario, Canada
Founded: 2015
Website: http://www.zucara.ca/
LinkedIn: https://www.linkedin.com/company/zucara-therapeutics-inc-/
Twitter: https://twitter.com/zucara_ca
Crunchbase: https://www.crunchbase.com/organization/zucara-therapeutics
Leave a Comment
Comments
No comments yet.